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OBJECTIVES We sought to investigate, during a two-year follow-up period, the effects of aspirin on platelet
aggregation.
BACKGROUND The platelets of patients given aspirin may be less sensitive to antiplatelet treatment, although
the extent of such phenomenon over long-term follow-up is unclear.
METHODS Adenosine diphosphate (ADP) and collagen-induced platelet aggregation was periodically
monitored before and after 2, 6, 12, and 24 months of treatment with aspirin (n  150) or
ticlopidine (n  80) in patients matched for gender, age, and risk factors for atherothrom-
bosis.
RESULTS Compared with baseline values, two months of aspirin treatment significantly inhibited
platelet aggregation; thereafter, this inhibitory effect progressively decreased. At 24-month
follow-up, collagen-induced platelet aggregation was significantly higher than that observed
at two months (p  0.05); a more pronounced difference was observed when collagen-
induced lag phase was considered (p  0.01). Restoration of platelet aggregation was less
evident when ADP was used as an agonist. Conversely, the inhibition induced by ticlopidine
was constant throughout follow-up with both agonists.
CONCLUSIONS The study demonstrates that a long-term treatment with aspirin is associated with a
progressive reduction in platelet sensitivity to this drug. (J Am Coll Cardiol 2004;43:
979–84) © 2004 by the American College of Cardiology Foundationi
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ccetylsalicylic acid (aspirin) is an antiplatelet agent that
nhibits platelet cyclooxygenase-1 (COX-1) and, as a con-
equence, prevents the formation of the pro-aggregatory
ubstance, thromboxane A2 (TXA2). Although the clinical
fficacy of aspirin in acute coronary syndromes has been well
stablished, the evidence of its beneficial effects after myo-
ardial infarction is based on a meta-analysis (1). It is also
oteworthy that meta-analysis of antiplatelet therapy dem-
nstrated a progressive decrease of aspirin’s clinical efficacy,
articularly after two years of treatment (1). However, it has
ever been investigated whether this phenomenon is simply
ue to chance or whether prolonged treatment might
rovoke a reduced sensitivity to aspirin. Furthermore, pre-
ious studies have demonstrated an increased risk of cardio-
ascular events in patients with either acute coronary syn-
romes or undergoing invasive strategies and who were
aking aspirin (2,3). Two previous studies analyzed the
ehavior of platelet aggregation in patients undergoing
rolonged aspirin treatment, but the results were divergent
4,5). To further explore this issue, we have analyzed
latelet aggregation in response to several agonists in
atients treated with aspirin or ticlopidine for at least 24
onths. We report, for the first time, that while the
latelets of patients taking ticlopidine show a similar rate of
From the Department of Experimental Medicine and Pathology, University “La
apienza,” Rome, Italy. This study was partially supported by a grant from the Italian
inistry of Instruction, University and Scientific Research (MIUR) ex 60% Ateneo
001, to Dr. Pulcinelli.”
Manuscript received May 26, 2003; revised manuscript received July 11, 2003,accepted August 5, 2003.nhibition during follow-up, the platelets of patients taking
spirin become less sensitive to antiplatelet treatment.
ETHODS
etween 1997 and 2001, patients with clinical evidence of
therothrombosis were studied to check for platelet aggre-
ation before and after antiplatelet treatment. Platelet ag-
regation was performed to analyze whether platelets were
ensitive to the antiplatelet treatment chosen by the family
octor. Evaluation of platelet aggregation was retrospec-
ively performed according to the following criteria: 1)
ccomplishment of an in vitro platelet aggregation test
efore and during aspirin (100 or 330 mg/day) or ticlopidine
250 mg/day) treatment, following a precise monthly sched-
le (2 months  10 days, 6 months  15 days, 12  1
onth, and 24 1 month); 2) non-concurrent therapy with
ny other drug known to interfere with platelet function
e.g., non-steroidal anti-inflammatory drugs, corticoste-
oids, and the like); 3) compliance to aspirin treatment, as
ocumented by the absence or more than 90% reduction of
n in vitro platelet response to arachidonic acid at every test
erformed; and 4) the absence of acute coronary syndromes
r coronary intervention in the previous three months or any
ther disease linked to platelet function.
Among the 176 patients taking aspirin, 150 (64 men,
ean age 58 years [range 52 to 74 years]; 86 women, mean
ge 62 years [range 53 to 78 years]) met the inclusion
riteria. Twenty-six patients who responded to arachidonic
cid despite aspirin treatment (4 patients at 2 months; 5
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Aspirin Resistance in Long-Term Treated Patients March 17, 2004:979–84atients at 6 months, 8 patients at 12 months, and 9 patients
t 24 months) were not included in the study and analyzed
eparately.
Eighty out-patients matched for gender, age, and risk
actors for atherosclerosis and treated with ticlopidine
250 mg/day) instead of aspirin were enrolled with the same
nclusion criteria and used as the control group.
Patients were considered hypertensive if blood pressure
as 140/90 mm Hg in at least three different measure-
ents when patients were in a supine position for at least
0 min or if they were treated with antihypertensive drugs.
atients were considered hypercholesterolemic if serum
holesterol was 240 mg/dl or if they were treated with
ipid-lowering agents, and diabetic if they received treat-
ent with oral antidiabetics or insulin.
No difference in the prevalence of hypertension (45% vs.
1%), hypercholesterolemia (31% vs. 34%), diabetes (7.2%
s. 8.5%), and smoking (15.3% vs. 16.4%) was observed
etween ticlopidine and aspirin-treated patients, respec-
ively.
Blood samples anticoagulated with sodium citrate (ratio
:1) were taken from each patient after at least 12 h of
asting. As previously described (6), platelet aggregation
according to Born’s method) was evaluated considering the
aximal percentage (Mx%) of platelet aggregation in re-
ponse to 2 mol/l adenosine diphosphate (ADP) and 1
mol/l arachidonic acid, and Mx% as well as the lag phase
n response to 2 g/ml collagen. The lag phase was defined
s the delay time occurring between the addition of collagen
nd the beginning of the aggregation curve; the Mx% was
alculated as the light transmission difference between
latelet-rich plasma and platelet-poor plasma (100%). All of
he platelet agonists used and the aggregometer were from
elena BioSciences (Sunderland, United Kingdom); con-
urrent control studies were performed to ensure that all
gonists retained the same level of activity during the whole
tudy.
tatistical analysis. All data are reported as the mean value
SD and, where appropriate, as median values and ranges.
o compare the groups, analysis of variance was performed
or data normally distributed (lag phase), and post hoc
nalysis (Dunnett’s test) was used to test for changes from
aseline to post-treatment times. The Kruskal-Wallis test
as performed for skewed data (Mx% of platelet aggrega-
ion) to compare the different responses obtained before and
fter 2, 6, 12, or 24 months treatment. The Wilcoxon test
as performed to further confirm the significant differences
Abbreviations and Acronyms
ADP  adenosine diphosphate
COX-1  cyclooxygenase-1
Mx%  maximal percentage
TXA2  thromboxane A2
TXB2  thromboxane B2bserved between the two groups. Significance was accepted ot p  0.05. The statistical package used was SPSS version
.0 for Windows (SPSS Inc., Chicago, Illinois).
ESULTS
he collagen-induced lag phase before and after aspirin
reatment is reported in Figure 1. Compared with baseline,
he lag phase was significantly prolonged at two months
76.6  46.1 s vs. 36.1  18.1 s, p  0.001); such a
henomenon tended to progressively decrease at 6 (65.5 
1.5 s, pNS vs. 2 months) and 12 months (58.5 39.8 s,
 0.05 vs. 2 months) and became similar to that observed
t baseline after 24 months (42.5  23.8 s, p  0.001 vs. 2
onths). At 24 months, in 42% of patients, the lag phase
alues returned to baseline.
The Mx% of platelet aggregation in response to collagen
ecreased from 88.2  21.8% to 37.9  24.4% (p  0.001)
t 2 months. A progressive reduction of the aspirin effect
as observed at 6 (46.1  27.1%, p  NS vs. 2 months), 12
48.7  27.6%, p  NS vs. 2 months), and 24 months of
herapy (61.9  23.9%, p  0.05 vs. 2 months) (Fig. 2). At
4 months, 43% of patients had the same light transmission
alues as those observed at baseline.
The reduced sensitivity to aspirin during follow-up was
bserved also when ADP was used as an agonist, but its
ehavior was different. Compared with baseline values (85.1
igure 1. Box plot of the lag phase of platelet aggregation induced by
ollagen (2 g/ml) before and after 2, 6, 12, and 24 months of aspirin
reatment. NS  not significant.
igure 2. Box plot of the maximal percentage (Mx%) of platelet aggrega-
ion induced by collagen (2 g/ml) before and after 2, 6, 12, and 24 months
f aspirin treatment. NS  not significant.
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March 17, 2004:979–84 Aspirin Resistance in Long-Term Treated Patients12.4%), the rate of aggregation inhibition was less than
hat found with collagen, with values of 67.2  19.3% at 2
onths, 65.1 19.1% at 6 months, and 68.3 18.4% at 12
onths. After 24 months of therapy, the rate of inhibition
ecreased (71.2  16.2%, p  0.05 vs. 2 months) (Fig. 3),
ith 41% of patients whose values returned to baseline. A
eparate analysis has been performed after inclusion of the
6 patients who responded to arachidonic acid despite
spirin treatment. The results showed no changes when this
roup of patients was included in the statistical analysis
data not shown).
We analyzed whether the sensitivity to aspirin was
ependent on its dosage, but throughout the follow-up, no
ifference between patients given 100 mg/day or 300 to 330
g/day aspirin with either agonist was observed (Fig. 4).
latelet sensitivity to aspirin was similar both in hyperten-
ive and hypercholesterolemic patients (Fig. 5). The influ-
nce of smoking on platelet responses during aspirin treat-
ent was not taken into consideration, as 95% of patients
topped smoking concomitantly with the beginning of
ntiplatelet treatment; none of them resumed smoking
uring follow-up.
During the two-year follow-up, the aggregometric re-
ponses of patients treated with ticlopidine (250 mg/day)
howed a significant reduction at every time point analyzed
Table 1), the highest inhibition being found when ADP
as used as an agonist. There were, however, a certain
umber of patients who did not show any change of
DP-induced platelet aggregation during follow-up; there-
ore, they were considered non-responders (8.7%).
ISCUSSION
revious studies have demonstrated that patients taking
spirin have platelets that may respond to common agonists
7). By using an arbitrary unit of platelet resistance, Gum et
l. (7) found that about 10% to 20% of patients given aspirin
ompletely responded to one or more agonists immediately
fter the beginning of treatment. The uniqueness of our
tudy is that we performed long-term follow-up and peri-
igure 3. Box plot of the maximal percentage (Mx%) of platelet aggrega-
ion induced by adenosine diphosphate (ADP) (2 mol/l) before and after
, 6, 12, and 24 months of aspirin treatment. NS  not significant.dic monitoring of the platelet response to agonists. In this wtudy, we demonstrated that the inhibition of platelet
ggregation by aspirin progressively decreased no matter
igure 4. Platelet aggregation (meanSEM) analyzed as lag phase and maximal
ercentage (Mx%) of aggregation in response to collagen (2 g/ml) and as Mx%
n response to adenosine diphosphate (ADP) (2 mol/l) at baseline and through-
ut follow-up in patients given 100 mg/day or 300 to 330 mg/day aspirin.hich agonist was used. The loss of antiplatelet effect
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Aspirin Resistance in Long-Term Treated Patients March 17, 2004:979–84tarted after 6 to 12 months of treatment and was more
vident thereafter. It must be emphasized, however, that the
educed sensitivity to aspirin treatment was more evident
igure 5. Platelet aggregation (mean  SEM) analyzed as lag phase and
aximum percentage of aggregation (Mx%) in response to collagen (2
g/ml) and as Mx% in response to adenosine diphosphate (ADP) (2
mol/l) at baseline and throughout follow-up in hypertensive and hyper-
holesterolemic patients.
able 1. Collagen (2 g/ml) and Adenosine Diphosphate (2 m
Before
Treatment 2 Months
ollagen lag phase (s) 35.5  14.1 46.6  12.3*
ollagen (Mx%) 86.1  12.8 79.2  13.8*
DP (Mx%) 86.1  12.1 49.5  17.2†
p  0.05, †p  0.001 vs. baseline values. Data are reported as the mean value  S
ADP  adenosine diphosphate; Mx%  maximum percentage of platelet aggregation.sing collagen as an agonist; this could be dependent on the
ensitivity of the assay, as aspirin inhibits collagen-induced
latelet aggregation potently but has only a modest effect on
DP-induced platelet aggregation (8).
Two previous studies (4,5) have already analyzed the
ehavior of platelet aggregation during a long period of
ollow-up. Berglund and Wallentin (4) randomized 193
atients with unstable angina to placebo or 75 mg/day
spirin and performed repeated measurement up to
4 months of follow-up. In the aspirin group, no change of
DP-induced platelet aggregation was detected, whereas
ollagen-induced platelet aggregation was significantly in-
ibited throughout follow-up. A potential limitation of this
tudy was that in about half of the patients, baseline platelet
ggregation was not performed; furthermore, blood sam-
ling was obtained between 1 and 2 PM, thus a comparison
f these results with those of the present study is quite
ifficult. Helgason et al. (5) studied 306 aspirin-treated
atients with previous ischemic stroke and monitored plate-
et aggregation up to six months. Of the 306 patients
ecruited, 228 showed immediate inhibition of platelet
ggregation and 78 had partial inhibition. During follow-
p, only 119 patients with immediate and complete inhibi-
ion underwent repeat testing. Of these, 39 patients (32.7%)
ad lost part of this inhibitory effect, suggesting a reduced
ensitivity to aspirin. This finding is in accordance with the
esults of the present study, indicating that platelet sensi-
ivity to aspirin is progressively lost during long-term
reatment.
An important point that has not yet been considered is
hether platelet “resistance” to an antiplatelet drug is
pecific. To this purpose, we investigated whether a sort of
esistance to ticlopidine may be also observed by time. We
ound that in patients taking ticlopidine, which inhibits
latelet aggregation in response to ADP (9), platelet inhi-
ition was constant over time, suggesting that the progres-
ive reduction of the antiplatelet effect may be drug specific.
his comparison, however, is limited by the fact that the
iclopidine-treated group was not included in a randomized
tudy, but served only as a control group. Direct comparison
etween aspirin and ticlopidine should be tested in a future
tudy. However, it should be noted that also in the group
aking ticlopidine, a certain number of patients (8.7%) did
ot respond to treatment. This finding is consistent with the
esults of a recent study showing that after one month of
reatment with clopidogrel, another ADP receptor antago-
Induced Platelet Aggregation During Ticlopidine Treatment
6 Months 12 Months 24 Months
43.7  17.7* 48.5  19.9* 41.4  21.5*
76.7  17.5* 71.2  17.4* 76.1  19.2*
45.1  18.2† 49.6  19.4† 37.2  26.4†ol/l)
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March 17, 2004:979–84 Aspirin Resistance in Long-Term Treated Patientsist, 15% of patients who underwent coronary stenting did
ot show any change of platelet aggregation (10).
Patients taking aspirin have evident clinical benefits, as
emonstrated by a more recent meta-analysis (1), but it is
lso becoming evident that many patients are still at risk of
ardiovascular events, despite the regular consumption of
spirin (11). A recent study demonstrated that patients
aking aspirin who had elevated urinary excretion of 11-
ehydro-thromboxane B2 (TXB2) were at high risk of
ardiovascular events, suggesting that aspirin resistance
ight predispose to atherothrombotic complication (12).
owever, the authors did not investigate whether the
ersistent elevation of 11-dehydro-TXB2 was dependent on
ctivation of platelets or other cellular sources, such as
onocytes and macrophages, which are potentially respon-
ible for TXA2 formation. Platelet and extraplatelet mech-
nisms have been considered in explaining the resistance to
spirin (11). Even if the aim of our study was not to explore
he mechanism of aspirin resistance, our findings show that
espite aspirin treatment, platelet aggregation in response to
ommon agonists is progressively restored. A genetic basis
or explaining individual variations in response to aspirin,
uch as single-nucleotide polymorphisms of COX-1, may
epresent an intriguing mechanism that deserves further
nvestigation (11).
Another interesting possibility is provided by a recent
tudy demonstrating that under physiologic conditions,
latelets express a negligible amount of COX-2, whereas
ewly formed platelets have a detectable amount of COX-2,
hich may contribute to TXA2 biosynthesis (13). Presently,
e have no element to support the hypothesis that platelets
ecome less sensitive to aspirin as a consequence of COX-
–dependent TXA2 production; such a suggestion needs to
e investigated in a future study.
Even if we did not find any relationship between risk
actors at baseline and sensitivity to aspirin during follow-
p, we cannot be certain that other factors or modifications
f the aforementioned reported risk factors could affect
spirin efficiency; this issue deserves further investigation in
larger number of patients.
onclusions. We have demonstrated that in patients tak-
ng aspirin for a long period of time, platelets become
rogressively less sensitive to the drug. However, the clinical
mpact of this finding is limited by the lack of evidence that
atients who are not sensitive to aspirin are at a higher risk
f cardiovascular events. Using an aggregometric test, a
ecent study demonstrated that patients with “resistance” to
spirin were at a high risk of cardiovascular events (14).
hus, among the patients who were not sensitive to aspirin
herapy, the rate of cardiovascular events was 24%, com-
ared with 10% in patients who were sensitive to aspirin.
An intriguing finding of this study was the late diver-
ence of the Kaplan-Meier curves, suggesting that the risk
f cardiovascular events increased in relation to the duration
f treatment. As the increase in cardiovascular risk was
bserved after at least one year of treatment, our study mayrovide insight into the mechanism accounting for the late
ccurrence of cardiovascular events in aspirin-treated pa-
ients and could support recent trials suggesting the need of
dding other antiplatelet agents, such as clopidogrel, to
spirin for early and late reduction of cardiovascular events
15). Of particular interest were the findings of the Clopi-
ogrel for the Reduction of Events During Observation
CREDO) trial (16), showing that prolonged treatment
ith such combined therapy reduced cardiovascular events,
ith a divergence of Kaplan-Meier curves that was more
vident after nine months of follow-up, compared with
spirin-treated patients. Future studies should therefore
ddress the question of whether the superiority of such a
ombination is dependent on a more complete and efficient
nhibition of platelet aggregation or on a protective effect
rovided by clopidogrel in patients with a progressively
educed sensitivity to aspirin.
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